| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neurosurgery | 24 | 2023 | 679 | 3.990 |
Why?
|
| Neuroma, Acoustic | 23 | 2023 | 458 | 2.790 |
Why?
|
| Neurosurgical Procedures | 31 | 2024 | 2067 | 2.540 |
Why?
|
| Meningioma | 26 | 2024 | 1216 | 2.490 |
Why?
|
| Brain Neoplasms | 60 | 2024 | 9025 | 2.180 |
Why?
|
| Meningeal Neoplasms | 20 | 2024 | 1246 | 2.040 |
Why?
|
| Craniotomy | 18 | 2016 | 741 | 1.840 |
Why?
|
| Craniopharyngioma | 9 | 2023 | 276 | 1.730 |
Why?
|
| Neurofibromatosis 2 | 10 | 2023 | 383 | 1.410 |
Why?
|
| Pituitary Neoplasms | 11 | 2023 | 1322 | 1.320 |
Why?
|
| Intracranial Aneurysm | 11 | 2011 | 1286 | 1.250 |
Why?
|
| Radiosurgery | 16 | 2022 | 1339 | 1.120 |
Why?
|
| Laminectomy | 4 | 2021 | 225 | 0.910 |
Why?
|
| Trigeminal Neuralgia | 6 | 2007 | 107 | 0.900 |
Why?
|
| Aneurysm, Ruptured | 6 | 2011 | 464 | 0.870 |
Why?
|
| Glioblastoma | 18 | 2024 | 3482 | 0.830 |
Why?
|
| Decompression, Surgical | 10 | 2016 | 607 | 0.810 |
Why?
|
| Cranial Irradiation | 9 | 2022 | 390 | 0.800 |
Why?
|
| Hospital Mortality | 16 | 2012 | 5295 | 0.800 |
Why?
|
| Spinal Stenosis | 5 | 2016 | 261 | 0.790 |
Why?
|
| Spondylolisthesis | 4 | 2016 | 172 | 0.740 |
Why?
|
| Postoperative Complications | 33 | 2023 | 15637 | 0.740 |
Why?
|
| Hydrocephalus | 6 | 2013 | 764 | 0.730 |
Why?
|
| Hemangioma, Cavernous, Central Nervous System | 2 | 2018 | 56 | 0.700 |
Why?
|
| Ventriculoperitoneal Shunt | 3 | 2011 | 187 | 0.660 |
Why?
|
| Supratentorial Neoplasms | 4 | 2009 | 159 | 0.600 |
Why?
|
| Central Nervous System Neoplasms | 5 | 2024 | 915 | 0.590 |
Why?
|
| Cerebrospinal Fluid Shunts | 3 | 2006 | 195 | 0.580 |
Why?
|
| Evidence-Based Medicine | 4 | 2012 | 3691 | 0.550 |
Why?
|
| Lumbar Vertebrae | 6 | 2016 | 1876 | 0.550 |
Why?
|
| Societies, Medical | 6 | 2014 | 3923 | 0.510 |
Why?
|
| Glioma | 15 | 2019 | 3452 | 0.510 |
Why?
|
| Hospital Charges | 7 | 2010 | 350 | 0.510 |
Why?
|
| Meta-Analysis as Topic | 2 | 2014 | 1381 | 0.490 |
Why?
|
| Proto-Oncogene Proteins B-raf | 5 | 2023 | 2054 | 0.470 |
Why?
|
| Neoplasm Recurrence, Local | 17 | 2022 | 9278 | 0.470 |
Why?
|
| Radiotherapy, Adjuvant | 13 | 2020 | 1784 | 0.450 |
Why?
|
| Humans | 216 | 2024 | 761222 | 0.450 |
Why?
|
| Hearing Loss | 7 | 2017 | 782 | 0.440 |
Why?
|
| Workload | 3 | 2004 | 845 | 0.440 |
Why?
|
| Isocitrate Dehydrogenase | 4 | 2024 | 937 | 0.430 |
Why?
|
| Vascular Surgical Procedures | 5 | 2009 | 1489 | 0.430 |
Why?
|
| Neurology | 2 | 2012 | 784 | 0.420 |
Why?
|
| Treatment Outcome | 53 | 2023 | 64681 | 0.420 |
Why?
|
| Centralized Hospital Services | 4 | 2005 | 18 | 0.420 |
Why?
|
| Length of Stay | 12 | 2012 | 6417 | 0.410 |
Why?
|
| Mutation | 21 | 2024 | 30004 | 0.400 |
Why?
|
| Nimodipine | 3 | 2017 | 56 | 0.400 |
Why?
|
| Spinal Cord Diseases | 3 | 2021 | 291 | 0.400 |
Why?
|
| Publishing | 2 | 2023 | 832 | 0.400 |
Why?
|
| Ventriculostomy | 1 | 2013 | 131 | 0.380 |
Why?
|
| Spondylosis | 3 | 2021 | 84 | 0.380 |
Why?
|
| Artificial Intelligence | 2 | 2023 | 2576 | 0.380 |
Why?
|
| Middle Aged | 108 | 2024 | 220858 | 0.380 |
Why?
|
| Adult | 108 | 2024 | 221120 | 0.380 |
Why?
|
| Laser Therapy | 2 | 2018 | 1094 | 0.370 |
Why?
|
| Facial Nerve | 4 | 2023 | 277 | 0.370 |
Why?
|
| Randomized Controlled Trials as Topic | 8 | 2018 | 10218 | 0.370 |
Why?
|
| Lymphoma | 2 | 2024 | 1898 | 0.370 |
Why?
|
| Telomerase | 6 | 2024 | 741 | 0.360 |
Why?
|
| Male | 124 | 2024 | 360703 | 0.350 |
Why?
|
| Aged | 84 | 2024 | 169292 | 0.350 |
Why?
|
| Molecular Targeted Therapy | 5 | 2019 | 2813 | 0.350 |
Why?
|
| Cervical Vertebrae | 4 | 2021 | 976 | 0.340 |
Why?
|
| Embolization, Therapeutic | 3 | 2009 | 1419 | 0.340 |
Why?
|
| Antibiotic Prophylaxis | 2 | 2007 | 637 | 0.330 |
Why?
|
| Congresses as Topic | 1 | 2014 | 803 | 0.330 |
Why?
|
| Female | 124 | 2024 | 392552 | 0.320 |
Why?
|
| Spinal Cord Compression | 2 | 2011 | 234 | 0.320 |
Why?
|
| Clinical Trials as Topic | 9 | 2017 | 8002 | 0.320 |
Why?
|
| Aged, 80 and over | 41 | 2024 | 58952 | 0.320 |
Why?
|
| Disease Progression | 17 | 2024 | 13511 | 0.320 |
Why?
|
| Retrospective Studies | 53 | 2024 | 80675 | 0.310 |
Why?
|
| Thrombolytic Therapy | 2 | 2010 | 2055 | 0.310 |
Why?
|
| Patient Selection | 5 | 2019 | 4246 | 0.310 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2012 | 495 | 0.310 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2020 | 628 | 0.300 |
Why?
|
| Cavernous Sinus | 3 | 2006 | 123 | 0.300 |
Why?
|
| United States | 38 | 2023 | 72341 | 0.300 |
Why?
|
| Angiogenesis Inhibitors | 3 | 2013 | 2047 | 0.290 |
Why?
|
| Neurofibromin 2 | 3 | 2024 | 269 | 0.290 |
Why?
|
| Hospitals | 6 | 2012 | 3881 | 0.290 |
Why?
|
| Review Literature as Topic | 2 | 2009 | 348 | 0.280 |
Why?
|
| Otologic Surgical Procedures | 2 | 2012 | 150 | 0.280 |
Why?
|
| Cranial Nerve Neoplasms | 2 | 2006 | 134 | 0.280 |
Why?
|
| Socioeconomic Factors | 6 | 2023 | 7804 | 0.280 |
Why?
|
| Databases, Factual | 11 | 2018 | 7965 | 0.270 |
Why?
|
| Research Design | 6 | 2018 | 6180 | 0.270 |
Why?
|
| Subarachnoid Hemorrhage | 5 | 2009 | 1033 | 0.270 |
Why?
|
| Facial Paralysis | 2 | 2023 | 346 | 0.270 |
Why?
|
| Seizures | 4 | 2016 | 2965 | 0.270 |
Why?
|
| Awards and Prizes | 2 | 2014 | 362 | 0.260 |
Why?
|
| Hospitals, Teaching | 2 | 2012 | 1155 | 0.260 |
Why?
|
| Skull Base Neoplasms | 4 | 2017 | 270 | 0.260 |
Why?
|
| Spinal Fusion | 4 | 2021 | 1294 | 0.260 |
Why?
|
| Adolescent | 46 | 2020 | 88300 | 0.250 |
Why?
|
| Meningitis | 1 | 2007 | 217 | 0.250 |
Why?
|
| Combined Modality Therapy | 16 | 2019 | 8519 | 0.250 |
Why?
|
| Hearing Disorders | 2 | 2003 | 126 | 0.240 |
Why?
|
| Stereotaxic Techniques | 2 | 2005 | 555 | 0.240 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2010 | 1162 | 0.240 |
Why?
|
| Surgical Instruments | 3 | 2011 | 383 | 0.230 |
Why?
|
| Neoplasm Proteins | 3 | 2021 | 3594 | 0.230 |
Why?
|
| Marital Status | 1 | 2005 | 425 | 0.230 |
Why?
|
| Surgical Wound Infection | 6 | 2008 | 1530 | 0.230 |
Why?
|
| Foramen Magnum | 1 | 2024 | 41 | 0.220 |
Why?
|
| Genes, p53 | 3 | 2005 | 713 | 0.220 |
Why?
|
| Quinazolines | 1 | 2010 | 1371 | 0.220 |
Why?
|
| Healthcare Disparities | 2 | 2010 | 3354 | 0.220 |
Why?
|
| Pseudotumor Cerebri | 1 | 2005 | 107 | 0.220 |
Why?
|
| Education, Medical, Continuing | 1 | 2009 | 825 | 0.220 |
Why?
|
| Glossopharyngeal Nerve Diseases | 1 | 2003 | 10 | 0.220 |
Why?
|
| Follow-Up Studies | 28 | 2024 | 39127 | 0.220 |
Why?
|
| Health Services Accessibility | 2 | 2012 | 5426 | 0.220 |
Why?
|
| Protons | 5 | 2023 | 1111 | 0.220 |
Why?
|
| Hemifacial Spasm | 1 | 2003 | 24 | 0.220 |
Why?
|
| Quality of Life | 9 | 2022 | 13367 | 0.220 |
Why?
|
| Paresis | 2 | 2006 | 176 | 0.210 |
Why?
|
| Survival Analysis | 14 | 2019 | 10088 | 0.210 |
Why?
|
| Eligibility Determination | 1 | 2007 | 420 | 0.210 |
Why?
|
| Microsurgery | 4 | 2003 | 793 | 0.210 |
Why?
|
| Sphenoid Bone | 1 | 2003 | 177 | 0.200 |
Why?
|
| Semicircular Canals | 1 | 2004 | 203 | 0.200 |
Why?
|
| Vertigo | 1 | 2004 | 202 | 0.200 |
Why?
|
| Neurilemmoma | 2 | 2010 | 523 | 0.200 |
Why?
|
| Antineoplastic Agents | 5 | 2023 | 13632 | 0.190 |
Why?
|
| Seasons | 2 | 2012 | 1518 | 0.190 |
Why?
|
| Aphasia | 1 | 2003 | 192 | 0.190 |
Why?
|
| Prognosis | 24 | 2024 | 29688 | 0.190 |
Why?
|
| Proto-Oncogene Proteins c-akt | 5 | 2024 | 2455 | 0.190 |
Why?
|
| Vasospasm, Intracranial | 1 | 2004 | 214 | 0.190 |
Why?
|
| Gene Amplification | 1 | 2005 | 1084 | 0.190 |
Why?
|
| Brain Diseases | 2 | 2004 | 1545 | 0.190 |
Why?
|
| Myometrium | 2 | 1998 | 174 | 0.180 |
Why?
|
| Angioplasty | 1 | 2004 | 356 | 0.180 |
Why?
|
| Ataxia | 1 | 2003 | 305 | 0.180 |
Why?
|
| Stroke | 3 | 2012 | 9721 | 0.180 |
Why?
|
| Brain Ischemia | 3 | 2010 | 3032 | 0.180 |
Why?
|
| Audiometry, Pure-Tone | 2 | 2012 | 210 | 0.180 |
Why?
|
| Cerebellar Neoplasms | 2 | 2014 | 586 | 0.180 |
Why?
|
| Multivariate Analysis | 13 | 2014 | 12052 | 0.180 |
Why?
|
| Spinal Cord Neoplasms | 2 | 2014 | 261 | 0.180 |
Why?
|
| Tinnitus | 1 | 2023 | 196 | 0.180 |
Why?
|
| Parkinsonian Disorders | 1 | 2023 | 285 | 0.180 |
Why?
|
| Cranial Fossa, Posterior | 3 | 2006 | 134 | 0.170 |
Why?
|
| Cohort Studies | 18 | 2018 | 41496 | 0.170 |
Why?
|
| Databases as Topic | 3 | 2009 | 473 | 0.170 |
Why?
|
| Patient Admission | 2 | 2004 | 1365 | 0.170 |
Why?
|
| Intracranial Arteriovenous Malformations | 1 | 2003 | 366 | 0.170 |
Why?
|
| Central Nervous System Vascular Malformations | 1 | 2001 | 140 | 0.170 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2009 | 1425 | 0.170 |
Why?
|
| Maternal Mortality | 2 | 2013 | 301 | 0.170 |
Why?
|
| Cognition Disorders | 3 | 2019 | 3976 | 0.170 |
Why?
|
| Age Factors | 12 | 2014 | 18384 | 0.170 |
Why?
|
| Parkinson Disease | 2 | 2023 | 2867 | 0.160 |
Why?
|
| Child | 30 | 2020 | 80154 | 0.160 |
Why?
|
| Medical Staff, Hospital | 1 | 2003 | 601 | 0.160 |
Why?
|
| Magnetic Resonance Imaging | 22 | 2021 | 36415 | 0.160 |
Why?
|
| History, 20th Century | 5 | 2014 | 2765 | 0.160 |
Why?
|
| Specialization | 1 | 2004 | 778 | 0.160 |
Why?
|
| Cochlear Nerve | 3 | 2015 | 202 | 0.160 |
Why?
|
| Antimetabolites | 2 | 1996 | 129 | 0.160 |
Why?
|
| Neurologic Examination | 3 | 2017 | 915 | 0.150 |
Why?
|
| Chordoma | 2 | 2014 | 347 | 0.150 |
Why?
|
| Chromosome Aberrations | 3 | 2009 | 1767 | 0.150 |
Why?
|
| Sarcopenia | 1 | 2023 | 370 | 0.150 |
Why?
|
| Editorial Policies | 1 | 2023 | 458 | 0.150 |
Why?
|
| Paranasal Sinus Neoplasms | 3 | 2009 | 242 | 0.150 |
Why?
|
| Cyanides | 1 | 2018 | 82 | 0.150 |
Why?
|
| Survival Rate | 16 | 2024 | 12728 | 0.150 |
Why?
|
| Trephining | 1 | 1997 | 13 | 0.150 |
Why?
|
| Education, Medical | 1 | 2010 | 1725 | 0.150 |
Why?
|
| Ubiquitin Thiolesterase | 2 | 2020 | 455 | 0.150 |
Why?
|
| History, 19th Century | 5 | 2009 | 718 | 0.150 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2019 | 11733 | 0.150 |
Why?
|
| Quality of Health Care | 2 | 2010 | 4321 | 0.150 |
Why?
|
| International Classification of Diseases | 3 | 2013 | 915 | 0.150 |
Why?
|
| Guanidines | 1 | 2018 | 194 | 0.140 |
Why?
|
| Electric Stimulation Therapy | 1 | 2003 | 625 | 0.140 |
Why?
|
| Radiotherapy | 2 | 2006 | 1500 | 0.140 |
Why?
|
| Neoplasms, Neuroepithelial | 1 | 1997 | 42 | 0.140 |
Why?
|
| Prospective Studies | 21 | 2024 | 54437 | 0.140 |
Why?
|
| Prostheses and Implants | 2 | 2009 | 1273 | 0.140 |
Why?
|
| Dystrophin | 1 | 2018 | 281 | 0.140 |
Why?
|
| Hospitalization | 4 | 2015 | 10707 | 0.140 |
Why?
|
| Hearing Tests | 2 | 2017 | 121 | 0.140 |
Why?
|
| Regression Analysis | 7 | 2013 | 6345 | 0.140 |
Why?
|
| Brachytherapy | 2 | 2019 | 1223 | 0.140 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2021 | 592 | 0.140 |
Why?
|
| Postoperative Period | 4 | 2020 | 1818 | 0.140 |
Why?
|
| Risk Assessment | 7 | 2020 | 24022 | 0.140 |
Why?
|
| Glomerular Filtration Rate | 2 | 2024 | 2182 | 0.140 |
Why?
|
| Health Care Costs | 1 | 2010 | 3239 | 0.130 |
Why?
|
| Anticonvulsants | 2 | 2016 | 1910 | 0.130 |
Why?
|
| Child, Preschool | 17 | 2020 | 42225 | 0.130 |
Why?
|
| Hypesthesia | 1 | 1997 | 106 | 0.130 |
Why?
|
| Piracetam | 1 | 2016 | 88 | 0.130 |
Why?
|
| Auditory Brain Stem Implants | 1 | 2016 | 33 | 0.130 |
Why?
|
| Watchful Waiting | 1 | 2020 | 489 | 0.130 |
Why?
|
| Phenytoin | 1 | 2016 | 190 | 0.130 |
Why?
|
| Deoxyglucose | 1 | 1997 | 333 | 0.130 |
Why?
|
| Hearing | 3 | 2017 | 502 | 0.130 |
Why?
|
| Vision Disorders | 1 | 2003 | 1089 | 0.130 |
Why?
|
| Epilepsy | 1 | 2011 | 3304 | 0.130 |
Why?
|
| Tic Disorders | 1 | 1997 | 136 | 0.130 |
Why?
|
| Cranial Nerve Injuries | 1 | 2015 | 28 | 0.130 |
Why?
|
| Bromodeoxyuridine | 1 | 1996 | 310 | 0.130 |
Why?
|
| Phrenology | 1 | 1995 | 5 | 0.130 |
Why?
|
| Gonadal Steroid Hormones | 2 | 1998 | 702 | 0.130 |
Why?
|
| Carcinoma, Adenoid Cystic | 2 | 2009 | 262 | 0.130 |
Why?
|
| Sphenoid Sinus | 3 | 2009 | 99 | 0.130 |
Why?
|
| Patient Satisfaction | 2 | 2007 | 3453 | 0.130 |
Why?
|
| Auditory Brain Stem Implantation | 1 | 2015 | 15 | 0.130 |
Why?
|
| Pain, Intractable | 1 | 1996 | 132 | 0.120 |
Why?
|
| Odds Ratio | 6 | 2019 | 9652 | 0.120 |
Why?
|
| Young Adult | 18 | 2024 | 59222 | 0.120 |
Why?
|
| Spine | 1 | 2002 | 1129 | 0.120 |
Why?
|
| Hearing Loss, Bilateral | 1 | 2015 | 53 | 0.120 |
Why?
|
| Kaplan-Meier Estimate | 8 | 2019 | 6486 | 0.120 |
Why?
|
| Rhabdoid Tumor | 1 | 2017 | 210 | 0.120 |
Why?
|
| Obesity | 2 | 2007 | 12940 | 0.120 |
Why?
|
| Trigeminal Nerve | 1 | 1996 | 248 | 0.120 |
Why?
|
| Spasm | 1 | 1995 | 130 | 0.120 |
Why?
|
| Hemangioblastoma | 1 | 2014 | 62 | 0.120 |
Why?
|
| Brain Injuries | 2 | 1997 | 2054 | 0.120 |
Why?
|
| Carcinoma, Papillary | 1 | 2019 | 785 | 0.110 |
Why?
|
| Fibrinolytic Agents | 1 | 2004 | 2075 | 0.110 |
Why?
|
| Oximes | 1 | 2015 | 303 | 0.110 |
Why?
|
| Spinal Neoplasms | 2 | 2012 | 703 | 0.110 |
Why?
|
| Facial Muscles | 1 | 1995 | 159 | 0.110 |
Why?
|
| Streptococcal Infections | 2 | 2010 | 617 | 0.110 |
Why?
|
| History, 21st Century | 2 | 2014 | 1567 | 0.110 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2021 | 1372 | 0.110 |
Why?
|
| Valine | 1 | 2015 | 408 | 0.110 |
Why?
|
| Fluorine Radioisotopes | 1 | 1997 | 420 | 0.110 |
Why?
|
| Skull Base | 1 | 2016 | 292 | 0.110 |
Why?
|
| Cause of Death | 2 | 2004 | 3688 | 0.110 |
Why?
|
| von Hippel-Lindau Disease | 1 | 2015 | 151 | 0.110 |
Why?
|
| Bacterial Infections | 2 | 2009 | 1390 | 0.110 |
Why?
|
| Premedication | 1 | 1994 | 246 | 0.110 |
Why?
|
| Anniversaries and Special Events | 1 | 2014 | 95 | 0.110 |
Why?
|
| Disease Management | 2 | 2016 | 2507 | 0.110 |
Why?
|
| Gene Deletion | 2 | 2018 | 2658 | 0.110 |
Why?
|
| Conflict of Interest | 1 | 2018 | 554 | 0.110 |
Why?
|
| Facial Nerve Diseases | 1 | 2013 | 49 | 0.110 |
Why?
|
| Hospital Departments | 1 | 1993 | 134 | 0.110 |
Why?
|
| Face | 3 | 2023 | 1025 | 0.110 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 3 | 2024 | 899 | 0.110 |
Why?
|
| Time Factors | 11 | 2016 | 39957 | 0.110 |
Why?
|
| Gene Targeting | 1 | 2016 | 838 | 0.110 |
Why?
|
| Neurofibroma, Plexiform | 1 | 2013 | 66 | 0.110 |
Why?
|
| Otolaryngology | 1 | 2020 | 693 | 0.110 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2014 | 305 | 0.110 |
Why?
|
| Pyrimidinones | 1 | 2015 | 385 | 0.110 |
Why?
|
| Internship and Residency | 2 | 2014 | 5885 | 0.100 |
Why?
|
| Tumor Necrosis Factor Receptor-Associated Peptides and Proteins | 2 | 2024 | 44 | 0.100 |
Why?
|
| Logistic Models | 6 | 2015 | 13249 | 0.100 |
Why?
|
| Infant | 12 | 2020 | 36170 | 0.100 |
Why?
|
| Calcium Channel Blockers | 1 | 1996 | 691 | 0.100 |
Why?
|
| Reoperation | 7 | 2016 | 4303 | 0.100 |
Why?
|
| Intracranial Hemorrhages | 1 | 2018 | 809 | 0.100 |
Why?
|
| Pharmaceutical Preparations | 1 | 2020 | 1086 | 0.100 |
Why?
|
| Risk Factors | 14 | 2024 | 74241 | 0.100 |
Why?
|
| Cerebral Hemorrhage | 2 | 2016 | 2642 | 0.100 |
Why?
|
| Internet | 3 | 2010 | 3096 | 0.100 |
Why?
|
| Drug Industry | 1 | 2018 | 788 | 0.100 |
Why?
|
| Cranial Nerves | 2 | 2021 | 98 | 0.100 |
Why?
|
| Carotid Artery, Internal | 1 | 1994 | 445 | 0.100 |
Why?
|
| Deafness | 1 | 2016 | 460 | 0.100 |
Why?
|
| Vascular Endothelial Growth Factor A | 3 | 2013 | 3493 | 0.100 |
Why?
|
| Antineoplastic Agents, Alkylating | 2 | 2008 | 617 | 0.100 |
Why?
|
| Delivery of Health Care | 1 | 2010 | 5333 | 0.100 |
Why?
|
| Chondrosarcoma | 1 | 2014 | 295 | 0.100 |
Why?
|
| Radiotherapy Dosage | 7 | 2009 | 2897 | 0.100 |
Why?
|
| Medulloblastoma | 1 | 1997 | 677 | 0.090 |
Why?
|
| Biopsy, Needle | 4 | 2005 | 1624 | 0.090 |
Why?
|
| Arteriovenous Fistula | 1 | 1994 | 319 | 0.090 |
Why?
|
| Neoplasms | 3 | 2015 | 22142 | 0.090 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2019 | 5665 | 0.090 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2013 | 588 | 0.090 |
Why?
|
| Proportional Hazards Models | 8 | 2019 | 12474 | 0.090 |
Why?
|
| Monte Carlo Method | 1 | 1996 | 1256 | 0.090 |
Why?
|
| Vasodilator Agents | 1 | 2015 | 989 | 0.090 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2020 | 2803 | 0.090 |
Why?
|
| Linear Models | 2 | 2011 | 5869 | 0.090 |
Why?
|
| Guidelines as Topic | 1 | 2017 | 1385 | 0.090 |
Why?
|
| Neoplasm, Residual | 1 | 2015 | 1008 | 0.090 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2015 | 610 | 0.090 |
Why?
|
| Cauda Equina | 1 | 2010 | 45 | 0.090 |
Why?
|
| Promoter Regions, Genetic | 5 | 2024 | 5773 | 0.090 |
Why?
|
| Neuroprotective Agents | 1 | 2017 | 956 | 0.090 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2024 | 2254 | 0.090 |
Why?
|
| Pyridones | 1 | 2015 | 809 | 0.090 |
Why?
|
| Pregnancy Complications | 2 | 2015 | 2949 | 0.090 |
Why?
|
| Confidence Intervals | 2 | 2019 | 2928 | 0.090 |
Why?
|
| Fusobacterium Infections | 1 | 2010 | 53 | 0.080 |
Why?
|
| Glutamic Acid | 1 | 2015 | 1173 | 0.080 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2012 | 258 | 0.080 |
Why?
|
| Pathology, Molecular | 1 | 2013 | 329 | 0.080 |
Why?
|
| Necrosis | 3 | 2005 | 1610 | 0.080 |
Why?
|
| Cerebral Revascularization | 1 | 2012 | 259 | 0.080 |
Why?
|
| DNA, Neoplasm | 2 | 2024 | 1743 | 0.080 |
Why?
|
| Neurofibromatoses | 1 | 2013 | 299 | 0.080 |
Why?
|
| Recurrence | 7 | 2017 | 8457 | 0.080 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2020 | 858 | 0.080 |
Why?
|
| Imidazoles | 1 | 2015 | 1172 | 0.080 |
Why?
|
| Inpatients | 2 | 2011 | 2545 | 0.080 |
Why?
|
| Peripheral Nervous System Neoplasms | 1 | 2010 | 133 | 0.080 |
Why?
|
| Hospitals, General | 1 | 1993 | 799 | 0.080 |
Why?
|
| Brain Abscess | 1 | 2010 | 120 | 0.080 |
Why?
|
| Morbidity | 3 | 2003 | 1751 | 0.080 |
Why?
|
| Statistics, Nonparametric | 2 | 2010 | 2854 | 0.080 |
Why?
|
| Ischemic Attack, Transient | 2 | 1996 | 874 | 0.080 |
Why?
|
| Patient Discharge | 3 | 2010 | 3441 | 0.080 |
Why?
|
| Data Interpretation, Statistical | 2 | 2011 | 2691 | 0.080 |
Why?
|
| Tumor Burden | 3 | 2014 | 1892 | 0.080 |
Why?
|
| Cochlea | 1 | 2015 | 846 | 0.080 |
Why?
|
| Endpoint Determination | 1 | 2011 | 590 | 0.080 |
Why?
|
| Frontal Lobe | 1 | 1995 | 1416 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 2009 | 277 | 0.080 |
Why?
|
| Disease-Free Survival | 6 | 2017 | 6819 | 0.080 |
Why?
|
| Skull | 2 | 2008 | 818 | 0.080 |
Why?
|
| Clinical Competence | 1 | 2004 | 4788 | 0.070 |
Why?
|
| Pneumocephalus | 1 | 2008 | 47 | 0.070 |
Why?
|
| Telangiectasia, Hereditary Hemorrhagic | 1 | 2010 | 141 | 0.070 |
Why?
|
| Neurofibromatosis 1 | 1 | 2013 | 561 | 0.070 |
Why?
|
| Sex Factors | 5 | 2020 | 10553 | 0.070 |
Why?
|
| Encephalocele | 1 | 2009 | 135 | 0.070 |
Why?
|
| Obstetric Labor, Premature | 3 | 2015 | 272 | 0.070 |
Why?
|
| Tracheotomy | 1 | 2008 | 167 | 0.070 |
Why?
|
| Drug Administration Schedule | 1 | 2015 | 4851 | 0.070 |
Why?
|
| Cognition | 2 | 2016 | 6988 | 0.070 |
Why?
|
| Computers, Handheld | 1 | 2009 | 210 | 0.070 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2016 | 2864 | 0.070 |
Why?
|
| Arteriovenous Malformations | 1 | 2010 | 396 | 0.070 |
Why?
|
| DNA-Binding Proteins | 3 | 2020 | 9567 | 0.070 |
Why?
|
| Tuberous Sclerosis | 1 | 2015 | 1031 | 0.070 |
Why?
|
| Loss of Heterozygosity | 1 | 2009 | 662 | 0.070 |
Why?
|
| Ear, Inner | 2 | 2009 | 425 | 0.070 |
Why?
|
| Pregnancy Outcome | 2 | 2015 | 2923 | 0.070 |
Why?
|
| Predictive Value of Tests | 8 | 2015 | 15308 | 0.070 |
Why?
|
| Supine Position | 1 | 2007 | 205 | 0.070 |
Why?
|
| Safety Management | 1 | 2012 | 761 | 0.070 |
Why?
|
| Thyroid Neoplasms | 1 | 2019 | 2330 | 0.070 |
Why?
|
| Bibliography of Medicine | 1 | 2005 | 3 | 0.070 |
Why?
|
| Enzyme Inhibitors | 1 | 1997 | 3702 | 0.070 |
Why?
|
| Fasciitis | 1 | 1987 | 67 | 0.070 |
Why?
|
| Carotid Artery Diseases | 1 | 2012 | 877 | 0.060 |
Why?
|
| Statistics as Topic | 3 | 2003 | 2359 | 0.060 |
Why?
|
| Bayes Theorem | 2 | 2005 | 2329 | 0.060 |
Why?
|
| Prone Position | 1 | 2007 | 196 | 0.060 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 1995 | 2820 | 0.060 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2020 | 697 | 0.060 |
Why?
|
| Speech Perception | 1 | 2010 | 508 | 0.060 |
Why?
|
| Fellowships and Scholarships | 1 | 2014 | 1115 | 0.060 |
Why?
|
| Databases, Bibliographic | 1 | 2005 | 130 | 0.060 |
Why?
|
| Facial Pain | 1 | 2006 | 120 | 0.060 |
Why?
|
| Otorhinolaryngologic Surgical Procedures | 1 | 2008 | 324 | 0.060 |
Why?
|
| Astrocytoma | 3 | 2002 | 774 | 0.060 |
Why?
|
| Dacarbazine | 1 | 2008 | 559 | 0.060 |
Why?
|
| Brain Stem | 2 | 2016 | 858 | 0.060 |
Why?
|
| Foundations | 1 | 2005 | 95 | 0.060 |
Why?
|
| Genomics | 2 | 2020 | 5829 | 0.060 |
Why?
|
| Infant, Newborn | 5 | 2020 | 26200 | 0.060 |
Why?
|
| Brain Infarction | 1 | 2006 | 289 | 0.060 |
Why?
|
| DNA Mutational Analysis | 3 | 2024 | 4107 | 0.060 |
Why?
|
| Mathematical Computing | 1 | 2004 | 142 | 0.060 |
Why?
|
| Physicians | 3 | 2009 | 4584 | 0.060 |
Why?
|
| Quality Improvement | 1 | 2019 | 3808 | 0.060 |
Why?
|
| Cisterna Magna | 1 | 2004 | 39 | 0.060 |
Why?
|
| Remission Induction | 2 | 2023 | 2392 | 0.060 |
Why?
|
| Ki-67 Antigen | 2 | 2017 | 628 | 0.060 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2010 | 781 | 0.060 |
Why?
|
| Cranial Fossa, Middle | 1 | 2004 | 29 | 0.060 |
Why?
|
| Prevalence | 3 | 2024 | 15721 | 0.060 |
Why?
|
| Hospital Records | 1 | 2004 | 93 | 0.060 |
Why?
|
| RNA Polymerase III | 1 | 2024 | 57 | 0.060 |
Why?
|
| Gyrus Cinguli | 1 | 2010 | 1114 | 0.060 |
Why?
|
| Genotype | 1 | 2018 | 12985 | 0.060 |
Why?
|
| Transcription Factors | 2 | 2020 | 12101 | 0.060 |
Why?
|
| Carrier Proteins | 1 | 1997 | 4935 | 0.050 |
Why?
|
| Health Facility Size | 1 | 2003 | 61 | 0.050 |
Why?
|
| Adenoma | 3 | 2006 | 2159 | 0.050 |
Why?
|
| Alkynes | 1 | 2024 | 320 | 0.050 |
Why?
|
| Carmustine | 1 | 2003 | 137 | 0.050 |
Why?
|
| Nevirapine | 1 | 2024 | 273 | 0.050 |
Why?
|
| Ghana | 1 | 2024 | 315 | 0.050 |
Why?
|
| Brain | 9 | 2022 | 27094 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 2 | 2020 | 7400 | 0.050 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2004 | 186 | 0.050 |
Why?
|
| Surgical Procedures, Operative | 2 | 2005 | 1923 | 0.050 |
Why?
|
| Radiography | 3 | 2021 | 6974 | 0.050 |
Why?
|
| Utilization Review | 1 | 2004 | 382 | 0.050 |
Why?
|
| Peer Review | 1 | 2005 | 217 | 0.050 |
Why?
|
| Diagnosis-Related Groups | 1 | 2004 | 448 | 0.050 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3093 | 0.050 |
Why?
|
| Cyclopropanes | 1 | 2024 | 432 | 0.050 |
Why?
|
| Publications | 1 | 2005 | 194 | 0.050 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3215 | 0.050 |
Why?
|
| Benzoxazines | 1 | 2024 | 316 | 0.050 |
Why?
|
| Phototherapy | 1 | 2006 | 368 | 0.050 |
Why?
|
| Medical Oncology | 1 | 2014 | 2320 | 0.050 |
Why?
|
| Hospital Bed Capacity | 1 | 2003 | 206 | 0.050 |
Why?
|
| Emergencies | 1 | 2009 | 1217 | 0.050 |
Why?
|
| Treatment Failure | 2 | 2019 | 2643 | 0.050 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 1 | 2022 | 185 | 0.050 |
Why?
|
| Genes, Tumor Suppressor | 2 | 1997 | 1057 | 0.050 |
Why?
|
| Publication Bias | 1 | 2002 | 160 | 0.050 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2003 | 880 | 0.050 |
Why?
|
| Hospital Information Systems | 1 | 2004 | 394 | 0.050 |
Why?
|
| Choice Behavior | 1 | 2007 | 825 | 0.050 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2005 | 749 | 0.050 |
Why?
|
| Otitis Media | 1 | 2004 | 286 | 0.050 |
Why?
|
| Biomedical Research | 1 | 2017 | 3434 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2006 | 1240 | 0.050 |
Why?
|
| Analysis of Variance | 2 | 2001 | 6223 | 0.050 |
Why?
|
| Karnofsky Performance Status | 2 | 2003 | 166 | 0.050 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2024 | 504 | 0.050 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 2 | 2001 | 326 | 0.050 |
Why?
|
| Lung Neoplasms | 3 | 2019 | 13386 | 0.040 |
Why?
|
| Research Support as Topic | 1 | 2005 | 697 | 0.040 |
Why?
|
| Cushing Syndrome | 2 | 1999 | 241 | 0.040 |
Why?
|
| Nerve Compression Syndromes | 2 | 2006 | 160 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2023 | 636 | 0.040 |
Why?
|
| Adenoviridae | 1 | 2004 | 1084 | 0.040 |
Why?
|
| Intubation, Intratracheal | 1 | 2008 | 1331 | 0.040 |
Why?
|
| Cesarean Section | 3 | 2015 | 1399 | 0.040 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2020 | 2915 | 0.040 |
Why?
|
| Cesium Radioisotopes | 1 | 2019 | 38 | 0.040 |
Why?
|
| Education, Medical, Graduate | 1 | 2012 | 2374 | 0.040 |
Why?
|
| Steroids | 1 | 2005 | 929 | 0.040 |
Why?
|
| Thromboplastin | 1 | 2001 | 286 | 0.040 |
Why?
|
| Cross-Sectional Studies | 3 | 2023 | 26072 | 0.040 |
Why?
|
| Diagnostic Imaging | 1 | 2013 | 3534 | 0.040 |
Why?
|
| Incidence | 4 | 2008 | 21366 | 0.040 |
Why?
|
| Wounds and Injuries | 1 | 2012 | 2493 | 0.040 |
Why?
|
| Body Mass Index | 2 | 2007 | 12952 | 0.040 |
Why?
|
| Insurance, Health | 1 | 2011 | 2493 | 0.040 |
Why?
|
| World Health Organization | 2 | 2015 | 1321 | 0.040 |
Why?
|
| Prolactin | 1 | 2001 | 625 | 0.040 |
Why?
|
| False Negative Reactions | 2 | 1997 | 573 | 0.040 |
Why?
|
| Fever | 1 | 2007 | 1618 | 0.040 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 2 | 2008 | 2787 | 0.040 |
Why?
|
| Endoscopy | 2 | 1999 | 1852 | 0.040 |
Why?
|
| Sex Chromatin | 1 | 2018 | 19 | 0.040 |
Why?
|
| Acromegaly | 2 | 1999 | 310 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 3 | 2017 | 3590 | 0.040 |
Why?
|
| Bone and Bones | 1 | 2009 | 2568 | 0.040 |
Why?
|
| Heart Arrest | 1 | 2009 | 1513 | 0.040 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2017 | 5321 | 0.040 |
Why?
|
| Fetal Growth Retardation | 2 | 2013 | 580 | 0.040 |
Why?
|
| Endometrium | 1 | 2001 | 403 | 0.040 |
Why?
|
| Vestibular Nerve | 1 | 1998 | 101 | 0.040 |
Why?
|
| Medicaid | 1 | 2011 | 2813 | 0.040 |
Why?
|
| Drug Delivery Systems | 2 | 2020 | 2223 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 2 | 2009 | 5493 | 0.040 |
Why?
|
| Decision Making | 1 | 2012 | 3931 | 0.040 |
Why?
|
| Anaplasia | 1 | 1997 | 16 | 0.040 |
Why?
|
| Attitude of Health Personnel | 1 | 2012 | 3885 | 0.040 |
Why?
|
| Connexin 43 | 1 | 1998 | 200 | 0.040 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2024 | 3634 | 0.040 |
Why?
|
| Histone Demethylases | 1 | 2020 | 322 | 0.040 |
Why?
|
| HIV Infections | 1 | 2024 | 17348 | 0.040 |
Why?
|
| Head | 1 | 2023 | 922 | 0.040 |
Why?
|
| Data Collection | 1 | 2007 | 3320 | 0.040 |
Why?
|
| Hospital Costs | 1 | 2003 | 947 | 0.040 |
Why?
|
| Health Resources | 1 | 2023 | 934 | 0.040 |
Why?
|
| Mitotic Index | 1 | 2017 | 162 | 0.040 |
Why?
|
| Venous Thrombosis | 1 | 2007 | 1304 | 0.040 |
Why?
|
| Canada | 1 | 2022 | 2125 | 0.040 |
Why?
|
| Meniere Disease | 1 | 1998 | 164 | 0.040 |
Why?
|
| Thalamus | 1 | 2003 | 1046 | 0.030 |
Why?
|
| Acute Disease | 2 | 2004 | 7226 | 0.030 |
Why?
|
| Silver | 1 | 1997 | 117 | 0.030 |
Why?
|
| Reproducibility of Results | 4 | 2023 | 20118 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 2 | 2015 | 6067 | 0.030 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2018 | 696 | 0.030 |
Why?
|
| Visual Fields | 1 | 2003 | 1061 | 0.030 |
Why?
|
| Immunohistochemistry | 4 | 2015 | 11067 | 0.030 |
Why?
|
| Intention to Treat Analysis | 1 | 2017 | 413 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 2 | 2009 | 9187 | 0.030 |
Why?
|
| Iodine Radioisotopes | 1 | 2019 | 1030 | 0.030 |
Why?
|
| Carcinoma in Situ | 1 | 2001 | 791 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 1994 | 7407 | 0.030 |
Why?
|
| Oligodendroglioma | 1 | 1997 | 278 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2015 | 15920 | 0.030 |
Why?
|
| Stromal Cells | 1 | 2001 | 1329 | 0.030 |
Why?
|
| Basilar Artery | 1 | 1996 | 205 | 0.030 |
Why?
|
| Vertebral Artery | 1 | 1996 | 184 | 0.030 |
Why?
|
| North Carolina | 1 | 2016 | 324 | 0.030 |
Why?
|
| Tumor Microenvironment | 2 | 2022 | 3875 | 0.030 |
Why?
|
| Wounds, Penetrating | 1 | 1997 | 314 | 0.030 |
Why?
|
| Polycystic Kidney Diseases | 1 | 1996 | 133 | 0.030 |
Why?
|
| Ganciclovir | 1 | 1995 | 253 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2005 | 2598 | 0.030 |
Why?
|
| Ethmoid Sinus | 1 | 1994 | 57 | 0.030 |
Why?
|
| Proto-Oncogenes | 1 | 1995 | 321 | 0.030 |
Why?
|
| Frozen Sections | 1 | 2015 | 153 | 0.030 |
Why?
|
| Academies and Institutes | 1 | 2017 | 318 | 0.030 |
Why?
|
| Cell Division | 3 | 2001 | 4451 | 0.030 |
Why?
|
| Lectins | 2 | 2007 | 489 | 0.030 |
Why?
|
| Meningeal Arteries | 1 | 1994 | 68 | 0.030 |
Why?
|
| Adipokines | 2 | 2007 | 307 | 0.030 |
Why?
|
| Uterus | 1 | 1998 | 651 | 0.030 |
Why?
|
| Ophthalmic Artery | 1 | 1994 | 58 | 0.030 |
Why?
|
| Pre-Eclampsia | 2 | 2015 | 1233 | 0.030 |
Why?
|
| Uterine Diseases | 1 | 1995 | 108 | 0.030 |
Why?
|
| Periodicals as Topic | 1 | 2005 | 1463 | 0.030 |
Why?
|
| Intraoperative Period | 1 | 2015 | 510 | 0.030 |
Why?
|
| Tissue Fixation | 1 | 2015 | 241 | 0.030 |
Why?
|
| Gap Junctions | 1 | 1995 | 230 | 0.030 |
Why?
|
| Skull Neoplasms | 1 | 1995 | 173 | 0.030 |
Why?
|
| Operating Rooms | 1 | 2020 | 790 | 0.030 |
Why?
|
| Radionuclide Imaging | 2 | 1997 | 1989 | 0.030 |
Why?
|
| Carcinoma | 1 | 2005 | 2330 | 0.030 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2009 | 4021 | 0.030 |
Why?
|
| Interferon-alpha | 1 | 1998 | 907 | 0.030 |
Why?
|
| Prodrugs | 1 | 1995 | 262 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2014 | 322 | 0.030 |
Why?
|
| Evoked Potentials, Auditory, Brain Stem | 1 | 2015 | 255 | 0.030 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 1999 | 732 | 0.030 |
Why?
|
| Bone Wires | 1 | 1994 | 124 | 0.030 |
Why?
|
| Gallbladder Neoplasms | 1 | 1995 | 189 | 0.030 |
Why?
|
| Tamoxifen | 1 | 1998 | 965 | 0.030 |
Why?
|
| Arteries | 2 | 1996 | 1121 | 0.030 |
Why?
|
| Genes, Dominant | 1 | 1996 | 850 | 0.030 |
Why?
|
| Pulmonary Embolism | 1 | 2007 | 2571 | 0.030 |
Why?
|
| Vestibulocochlear Nerve | 1 | 2013 | 115 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2018 | 2621 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2010 | 3512 | 0.030 |
Why?
|
| Recovery of Function | 1 | 2003 | 2981 | 0.030 |
Why?
|
| Forecasting | 1 | 2022 | 2928 | 0.030 |
Why?
|
| Patient Participation | 1 | 2002 | 1445 | 0.030 |
Why?
|
| Interferon-gamma | 1 | 2001 | 3155 | 0.030 |
Why?
|
| Spinal Cord | 1 | 2021 | 1807 | 0.030 |
Why?
|
| Capsicum | 1 | 1992 | 7 | 0.030 |
Why?
|
| Patient Readmission | 1 | 2007 | 3265 | 0.030 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2002 | 3770 | 0.030 |
Why?
|
| Gadolinium | 1 | 1997 | 961 | 0.030 |
Why?
|
| Neoplasm Staging | 2 | 2004 | 11119 | 0.020 |
Why?
|
| Indium Radioisotopes | 1 | 1992 | 113 | 0.020 |
Why?
|
| Scalp | 1 | 1995 | 389 | 0.020 |
Why?
|
| Simplexvirus | 1 | 1995 | 801 | 0.020 |
Why?
|
| Pharynx | 1 | 1994 | 432 | 0.020 |
Why?
|
| Equipment Failure | 1 | 1994 | 580 | 0.020 |
Why?
|
| Genetic Heterogeneity | 1 | 2015 | 734 | 0.020 |
Why?
|
| Paranasal Sinuses | 2 | 2009 | 265 | 0.020 |
Why?
|
| beta Catenin | 1 | 2016 | 1042 | 0.020 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2020 | 1878 | 0.020 |
Why?
|
| Plants, Medicinal | 1 | 1992 | 165 | 0.020 |
Why?
|
| Antigens, Tumor-Associated, Carbohydrate | 1 | 1992 | 138 | 0.020 |
Why?
|
| Chi-Square Distribution | 2 | 2010 | 3418 | 0.020 |
Why?
|
| Personality | 1 | 1995 | 553 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2008 | 20588 | 0.020 |
Why?
|
| Sensitivity and Specificity | 3 | 2019 | 14675 | 0.020 |
Why?
|
| Chronic Disease | 2 | 2004 | 9319 | 0.020 |
Why?
|
| Diagnosis, Differential | 4 | 2010 | 12976 | 0.020 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 1995 | 549 | 0.020 |
Why?
|
| Cerebral Infarction | 1 | 1996 | 981 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2009 | 22174 | 0.020 |
Why?
|
| Bone Plates | 1 | 1994 | 465 | 0.020 |
Why?
|
| Prosthesis Failure | 1 | 2016 | 1204 | 0.020 |
Why?
|
| Observer Variation | 1 | 2017 | 2610 | 0.020 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2021 | 2401 | 0.020 |
Why?
|
| Streptococcus anginosus | 1 | 2010 | 24 | 0.020 |
Why?
|
| Bone Screws | 1 | 1994 | 531 | 0.020 |
Why?
|
| Cranial Fossa, Anterior | 1 | 2009 | 13 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2018 | 3593 | 0.020 |
Why?
|
| Boston | 2 | 2012 | 9327 | 0.020 |
Why?
|
| Longitudinal Studies | 2 | 2004 | 14610 | 0.020 |
Why?
|
| Palliative Care | 1 | 2005 | 3599 | 0.020 |
Why?
|
| Postoperative Care | 1 | 2016 | 1468 | 0.020 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 1998 | 1520 | 0.020 |
Why?
|
| Epistaxis | 1 | 2010 | 112 | 0.020 |
Why?
|
| Neuropilin-2 | 1 | 2009 | 55 | 0.020 |
Why?
|
| Probability | 1 | 1995 | 2478 | 0.020 |
Why?
|
| Intestinal Neoplasms | 1 | 1992 | 315 | 0.020 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2001 | 2019 | 0.020 |
Why?
|
| Adenocarcinoma | 2 | 2009 | 6341 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2004 | 5081 | 0.020 |
Why?
|
| Cerebellum | 1 | 1996 | 1501 | 0.020 |
Why?
|
| Magnetic Resonance Angiography | 1 | 1996 | 1432 | 0.020 |
Why?
|
| Neuropilin-1 | 1 | 2009 | 90 | 0.020 |
Why?
|
| Glycoproteins | 2 | 2007 | 2203 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2016 | 2425 | 0.020 |
Why?
|
| Feasibility Studies | 2 | 2016 | 5250 | 0.020 |
Why?
|
| Gastric Mucosa | 1 | 1992 | 603 | 0.020 |
Why?
|
| Oropharynx | 1 | 2009 | 137 | 0.020 |
Why?
|
| Fusobacterium nucleatum | 1 | 2010 | 176 | 0.020 |
Why?
|
| Disability Evaluation | 1 | 2016 | 1834 | 0.020 |
Why?
|
| Germ-Line Mutation | 1 | 2017 | 1852 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2015 | 2706 | 0.020 |
Why?
|
| Osteotomy | 1 | 1994 | 836 | 0.020 |
Why?
|
| Anti-HIV Agents | 1 | 2024 | 4527 | 0.020 |
Why?
|
| Sclerosis | 1 | 1989 | 210 | 0.020 |
Why?
|
| Gene Silencing | 1 | 2014 | 1495 | 0.020 |
Why?
|
| Heart Atria | 1 | 1994 | 1349 | 0.020 |
Why?
|
| Antineoplastic Protocols | 1 | 2008 | 48 | 0.020 |
Why?
|
| Neoadjuvant Therapy | 1 | 2019 | 2827 | 0.020 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 1997 | 2024 | 0.020 |
Why?
|
| Activities of Daily Living | 1 | 2017 | 2420 | 0.020 |
Why?
|
| Central Nervous System Diseases | 1 | 1992 | 521 | 0.020 |
Why?
|
| Risk | 2 | 1996 | 9616 | 0.020 |
Why?
|
| Pregnancy | 3 | 2015 | 29893 | 0.020 |
Why?
|
| Radiography, Interventional | 1 | 1994 | 1122 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2009 | 638 | 0.020 |
Why?
|
| Ependymoma | 1 | 2010 | 320 | 0.020 |
Why?
|
| Hypertension, Pregnancy-Induced | 1 | 2013 | 518 | 0.020 |
Why?
|
| Neoplasms, Second Primary | 1 | 1995 | 1052 | 0.020 |
Why?
|
| Muscle Weakness | 1 | 2010 | 412 | 0.020 |
Why?
|
| Endometriosis | 1 | 1995 | 870 | 0.020 |
Why?
|
| Gangrene | 1 | 1987 | 91 | 0.020 |
Why?
|
| Age of Onset | 2 | 2006 | 3307 | 0.020 |
Why?
|
| Rhizotomy | 1 | 2006 | 30 | 0.020 |
Why?
|
| Neutrons | 1 | 2006 | 77 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2009 | 546 | 0.020 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2006 | 103 | 0.020 |
Why?
|
| Selection Bias | 1 | 2008 | 359 | 0.020 |
Why?
|
| Pain Measurement | 1 | 1996 | 3549 | 0.020 |
Why?
|
| Genes, Neurofibromatosis 2 | 1 | 2006 | 122 | 0.020 |
Why?
|
| Survivors | 1 | 2016 | 2369 | 0.020 |
Why?
|
| Thromboembolism | 1 | 1992 | 992 | 0.020 |
Why?
|
| Cell Survival | 1 | 1995 | 5778 | 0.020 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2009 | 339 | 0.020 |
Why?
|
| Depressive Disorder, Major | 1 | 2003 | 4767 | 0.020 |
Why?
|
| Adenovirus E1B Proteins | 1 | 2004 | 14 | 0.020 |
Why?
|
| Gene Dosage | 1 | 2009 | 1217 | 0.020 |
Why?
|
| Cadmium Compounds | 1 | 1984 | 15 | 0.020 |
Why?
|
| Delivery, Obstetric | 1 | 2012 | 941 | 0.010 |
Why?
|
| Heparin | 1 | 1992 | 1632 | 0.010 |
Why?
|
| Confusion | 1 | 2006 | 278 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 1994 | 6304 | 0.010 |
Why?
|
| Cerebral Arteries | 1 | 2006 | 490 | 0.010 |
Why?
|
| Pulmonary Veins | 1 | 2010 | 743 | 0.010 |
Why?
|
| Contrast Media | 1 | 1997 | 5311 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 2015 | 3461 | 0.010 |
Why?
|
| Injections, Subcutaneous | 2 | 1998 | 672 | 0.010 |
Why?
|
| Nasopharyngeal Neoplasms | 1 | 2006 | 290 | 0.010 |
Why?
|
| Injections, Intralesional | 1 | 2004 | 280 | 0.010 |
Why?
|
| Sarcoma | 1 | 1995 | 1800 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2014 | 4739 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2017 | 8642 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2018 | 12747 | 0.010 |
Why?
|
| Carbon | 1 | 2006 | 665 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2004 | 10756 | 0.010 |
Why?
|
| Computer Simulation | 1 | 1996 | 6224 | 0.010 |
Why?
|
| Survival | 1 | 2003 | 161 | 0.010 |
Why?
|
| Neovascularization, Pathologic | 1 | 2013 | 2636 | 0.010 |
Why?
|
| Preoperative Care | 2 | 2003 | 2241 | 0.010 |
Why?
|
| Biopsy | 2 | 2005 | 6781 | 0.010 |
Why?
|
| SEER Program | 1 | 2007 | 1453 | 0.010 |
Why?
|
| Microcirculation | 1 | 2006 | 1280 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2018 | 16954 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2017 | 10423 | 0.010 |
Why?
|
| Pulmonary Artery | 1 | 2010 | 1929 | 0.010 |
Why?
|
| Decidua | 1 | 2001 | 82 | 0.010 |
Why?
|
| Pain | 1 | 1996 | 5072 | 0.010 |
Why?
|
| Colposcopy | 1 | 2001 | 149 | 0.010 |
Why?
|
| Intestinal Mucosa | 1 | 1992 | 3031 | 0.010 |
Why?
|
| Absorbable Implants | 1 | 2003 | 338 | 0.010 |
Why?
|
| Choline | 1 | 2002 | 515 | 0.010 |
Why?
|
| Algorithms | 1 | 2021 | 14025 | 0.010 |
Why?
|
| Registries | 2 | 2010 | 8246 | 0.010 |
Why?
|
| Maximum Tolerated Dose | 1 | 2003 | 883 | 0.010 |
Why?
|
| Pandemics | 1 | 2020 | 8663 | 0.010 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2015 | 5301 | 0.010 |
Why?
|
| Genetic Variation | 1 | 2015 | 6567 | 0.010 |
Why?
|
| Neuropsychological Tests | 1 | 2013 | 7046 | 0.010 |
Why?
|
| Salvage Therapy | 1 | 2006 | 1264 | 0.010 |
Why?
|
| Cerebrospinal Fluid Otorrhea | 1 | 1999 | 15 | 0.010 |
Why?
|
| STAT1 Transcription Factor | 1 | 2001 | 340 | 0.010 |
Why?
|
| Intraoperative Care | 1 | 2003 | 767 | 0.010 |
Why?
|
| Paraneoplastic Endocrine Syndromes | 1 | 1999 | 29 | 0.010 |
Why?
|
| Viral Vaccines | 1 | 2004 | 593 | 0.010 |
Why?
|
| Protein Kinases | 1 | 2006 | 1607 | 0.010 |
Why?
|
| Functional Laterality | 1 | 2006 | 2257 | 0.010 |
Why?
|
| Hypophysectomy | 1 | 1999 | 114 | 0.010 |
Why?
|
| Software | 1 | 2013 | 4431 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2017 | 15841 | 0.010 |
Why?
|
| Animals | 5 | 2018 | 168089 | 0.010 |
Why?
|
| Matched-Pair Analysis | 1 | 1999 | 284 | 0.010 |
Why?
|
| Brain Edema | 1 | 2003 | 604 | 0.010 |
Why?
|
| Signal Transduction | 2 | 2015 | 23419 | 0.010 |
Why?
|
| Cytokines | 1 | 2013 | 7386 | 0.010 |
Why?
|
| Prolactinoma | 1 | 1999 | 113 | 0.010 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2001 | 384 | 0.010 |
Why?
|
| Disabled Persons | 2 | 1998 | 1224 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 2001 | 2263 | 0.010 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2006 | 2058 | 0.010 |
Why?
|
| Virus Replication | 1 | 2004 | 2426 | 0.010 |
Why?
|
| Cerebrovascular Circulation | 1 | 2006 | 2725 | 0.010 |
Why?
|
| Hysterectomy | 1 | 2001 | 857 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2015 | 12676 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2013 | 8998 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2006 | 4909 | 0.010 |
Why?
|
| Polymers | 1 | 2003 | 1617 | 0.010 |
Why?
|
| Skin Neoplasms | 1 | 1995 | 5809 | 0.010 |
Why?
|
| Thymidine Kinase | 1 | 1995 | 286 | 0.010 |
Why?
|
| Hyperplasia | 1 | 1998 | 1150 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2006 | 8300 | 0.010 |
Why?
|
| Cell Polarity | 1 | 1998 | 638 | 0.010 |
Why?
|
| Menorrhagia | 1 | 1995 | 59 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2004 | 3388 | 0.010 |
Why?
|
| Ovarian Neoplasms | 1 | 1992 | 4872 | 0.010 |
Why?
|
| Biocompatible Materials | 1 | 2003 | 1683 | 0.010 |
Why?
|
| Histiocytoma, Benign Fibrous | 1 | 1995 | 64 | 0.010 |
Why?
|
| Temporal Bone | 1 | 1999 | 683 | 0.010 |
Why?
|
| Bile | 1 | 1995 | 297 | 0.010 |
Why?
|
| Dysmenorrhea | 1 | 1995 | 98 | 0.010 |
Why?
|
| Decision Trees | 1 | 1996 | 505 | 0.010 |
Why?
|
| Mice | 2 | 2018 | 81330 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2009 | 9417 | 0.010 |
Why?
|
| Fibrosarcoma | 1 | 1995 | 308 | 0.010 |
Why?
|
| Chromosome Disorders | 1 | 1996 | 497 | 0.010 |
Why?
|
| Facial Bones | 1 | 1994 | 208 | 0.010 |
Why?
|
| Endoscopy, Digestive System | 1 | 1995 | 353 | 0.010 |
Why?
|
| Markov Chains | 1 | 1996 | 965 | 0.010 |
Why?
|
| Cell Differentiation | 2 | 2001 | 11512 | 0.010 |
Why?
|
| Azoxymethane | 1 | 1992 | 32 | 0.010 |
Why?
|
| Cephalometry | 1 | 1994 | 377 | 0.010 |
Why?
|
| Trans-Activators | 1 | 2001 | 2846 | 0.010 |
Why?
|
| Thrombophlebitis | 1 | 1992 | 289 | 0.010 |
Why?
|
| Cytodiagnosis | 1 | 1995 | 447 | 0.010 |
Why?
|
| Hydrocortisone | 1 | 1999 | 1818 | 0.010 |
Why?
|
| Cerebral Angiography | 1 | 1996 | 1281 | 0.010 |
Why?
|
| Rats, Inbred Strains | 1 | 1992 | 2087 | 0.010 |
Why?
|
| Bandages | 1 | 1992 | 269 | 0.010 |
Why?
|
| Administration, Oral | 1 | 1998 | 4015 | 0.010 |
Why?
|
| Kidney | 1 | 1984 | 7033 | 0.010 |
Why?
|
| Cardiovascular Diseases | 1 | 2015 | 15521 | 0.000 |
Why?
|
| Life Expectancy | 1 | 1996 | 1242 | 0.000 |
Why?
|
| Medicare | 1 | 2007 | 6774 | 0.000 |
Why?
|
| Tomography, Emission-Computed | 1 | 1992 | 1123 | 0.000 |
Why?
|
| Gene Expression | 1 | 2001 | 7571 | 0.000 |
Why?
|
| Cell Communication | 1 | 1995 | 1651 | 0.000 |
Why?
|
| Recombinant Proteins | 1 | 1998 | 6504 | 0.000 |
Why?
|
| Animals, Newborn | 1 | 1994 | 2665 | 0.000 |
Why?
|
| Tumor Cells, Cultured | 1 | 1995 | 6125 | 0.000 |
Why?
|
| Phenotype | 1 | 2006 | 16575 | 0.000 |
Why?
|
| Rats | 2 | 1995 | 23705 | 0.000 |
Why?
|
| Cell Cycle | 1 | 1995 | 2926 | 0.000 |
Why?
|
| Macaca mulatta | 1 | 1994 | 2328 | 0.000 |
Why?
|
| Lung | 1 | 2005 | 9979 | 0.000 |
Why?
|
| Nuclear Proteins | 1 | 2001 | 5783 | 0.000 |
Why?
|
| Cells, Cultured | 1 | 2001 | 18927 | 0.000 |
Why?
|
| Tellurium | 1 | 1984 | 23 | 0.000 |
Why?
|
| Technetium Tc 99m Pentetate | 1 | 1984 | 67 | 0.000 |
Why?
|
| Pentetic Acid | 1 | 1984 | 209 | 0.000 |
Why?
|
| Technetium | 1 | 1984 | 326 | 0.000 |
Why?
|
| Cadmium | 1 | 1984 | 215 | 0.000 |
Why?
|
| RNA | 1 | 1992 | 2709 | 0.000 |
Why?
|
| Ultrasonography | 1 | 1995 | 5969 | 0.000 |
Why?
|
| Radiometry | 1 | 1984 | 812 | 0.000 |
Why?
|
| DNA | 1 | 1992 | 7189 | 0.000 |
Why?
|
| Models, Biological | 1 | 1994 | 9458 | 0.000 |
Why?
|
| Proteins | 1 | 1992 | 5993 | 0.000 |
Why?
|